Amit Khera, M.D.
Executive Director, Genomic Medicine
Amit V. Khera is Executive Director, Genomic Medicine at Verve Therapeutics, where he applies over 15 years of training in clinical medicine and human genetics, to help enable Verve’s development of innovative treatments for cardiovascular disease.
Prior to joining Verve, he led a research program in the Massachusetts General Hospital’s Center for Genomic Medicine and Broad Institute of MIT and Harvard, focused on the use of human genetics to gain new biologic insights and enable enhanced clinical care. He pioneered a new approach to quantify genetic risk (‘genome-wide polygenic scores’) for common diseases, developed biomarkers that provide new biologic insights , and analyzed large-scale gene sequencing data to highlight key pathways driving risk and identify molecular subtypes of cardiometabolic diseases. In tandem with his research efforts, he was on faculty within the MGH Cardiovascular Medicine group and founded a new Preventive Genomics Clinic to provide a clinical infrastructure for genome-first medicine.
Dr. Khera has authored more than 100 scientific publications, including lead or senior-authored publications in the New England Journal of Medicine, Journal of the American Medical Association, Cell, Nature Reviews Genetics, Nature Genetics, Journal of the American College of Cardiology, and Circulation.
He completed his residency in internal medicine at Brigham and Women’s Hospital and fellowship in cardiovascular medicine at Massachusetts General Hospital prior to postdoctoral training in human genetics with Dr. Sekar Kathiresan at MGH and the Broad Institute. He received his M.D., with Alpha Omega Alpha distinction, from the Perelman School of Medicine at the University of Pennsylvania and a B.S. in Biology with summa cum laude distinction from Duke University.